KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $3.1 million.

  • Nektar Therapeutics' Share-based Compensation fell 4301.61% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 3658.73%. This contributed to the annual value of $21.6 million for FY2024, which is 3527.02% down from last year.
  • Per Nektar Therapeutics' latest filing, its Share-based Compensation stood at $3.1 million for Q3 2025, which was down 4301.61% from $3.5 million recorded in Q2 2025.
  • Nektar Therapeutics' Share-based Compensation's 5-year high stood at $24.7 million during Q3 2021, with a 5-year trough of $3.1 million in Q3 2025.
  • In the last 5 years, Nektar Therapeutics' Share-based Compensation had a median value of $8.1 million in 2023 and averaged $11.4 million.
  • In the last 5 years, Nektar Therapeutics' Share-based Compensation soared by 418.3% in 2021 and then crashed by 5317.96% in 2022.
  • Nektar Therapeutics' Share-based Compensation (Quarter) stood at $22.4 million in 2021, then plummeted by 43.15% to $12.7 million in 2022, then plummeted by 43.05% to $7.3 million in 2023, then tumbled by 33.79% to $4.8 million in 2024, then tumbled by 36.04% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.5 million for Q2 2025, and $3.9 million during Q1 2025.